Trial Outcomes & Findings for Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001) (NCT NCT00543387)

Last Updated: 2024-06-05

Results Overview

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who experienced an AE was reported for each dose level group.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

35 participants

Primary outcome timeframe

From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)

Results posted on

2024-06-05

Participant Flow

35 participants were enrolled and treated in this study. 14 enrolled into Panel 1 and received MK-5108 monotherapy. An additional 4 enrolled into Panel 1 and received MK-5108 as monotherapy prior to crossing over to Panel 2 and receiving MK-5108 with docetaxel. 17 enrolled into Panel 2 and received only the combination of MK-5108 and docetaxel.

Participant milestones

Participant milestones
Measure	MK-5108 200 mg BID (Panel 1) Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 400 mg BID (Panel 1) Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 800 mg BID (Panel 1) Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1200 mg BID (Panel 1) Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1500 mg BID (Panel 1) Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1800 mg BID (Panel 1) Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2) Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2) Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2) Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover) After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover) After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
Panel 1 + Panel 2 STARTED	3	3	3	3	3	3	6	6	5	0	0
Panel 1 + Panel 2 Crossed Over to Panel 2 Due to PD	0	1	0	0	2	1	0	0	0	0	0
Panel 1 + Panel 2 COMPLETED	0	0	0	0	0	0	0	0	0	0	0
Panel 1 + Panel 2 NOT COMPLETED	3	3	3	3	3	3	6	6	5	0	0
Crossover Participants STARTED	0	0	0	0	0	0	0	0	0	1	3
Crossover Participants COMPLETED	0	0	0	0	0	0	0	0	0	0	0
Crossover Participants NOT COMPLETED	0	0	0	0	0	0	0	0	0	1	3

Reasons for withdrawal

Reasons for withdrawal
Measure	MK-5108 200 mg BID (Panel 1) Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 400 mg BID (Panel 1) Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 800 mg BID (Panel 1) Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1200 mg BID (Panel 1) Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1500 mg BID (Panel 1) Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1800 mg BID (Panel 1) Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2) Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2) Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2) Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover) After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover) After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
Panel 1 + Panel 2 Adverse Event	0	1	0	0	0	0	0	1	1	0	0
Panel 1 + Panel 2 Physician Decision	0	0	1	0	0	0	0	1	0	0	0
Panel 1 + Panel 2 Progressive Disease (PD)	3	2	2	3	3	3	5	4	4	0	0
Panel 1 + Panel 2 Withdrawal by Subject	0	0	0	0	0	0	1	0	0	0	0
Crossover Participants Progressive Disease	0	0	0	0	0	0	0	0	0	1	2
Crossover Participants Study Terminated by Sponsor	0	0	0	0	0	0	0	0	0	0	1

Baseline Characteristics

Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	MK-5108 200 mg BID (Panel 1) n=3 Participants Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 400 mg BID (Panel 1) n=3 Participants Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 800 mg BID (Panel 1) n=3 Participants Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1200 mg BID (Panel 1) n=3 Participants Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1500 mg BID (Panel 1) n=3 Participants Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1800 mg BID (Panel 1) n=3 Participants Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=6 Participants Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=6 Participants Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=5 Participants Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	Total n=35 Participants Total of all reporting groups
Age, Continuous	54.0 years STANDARD_DEVIATION 11.4 • n=5 Participants	57.0 years STANDARD_DEVIATION 7.8 • n=7 Participants	75.3 years STANDARD_DEVIATION 9.1 • n=5 Participants	58.0 years STANDARD_DEVIATION 15.7 • n=4 Participants	54.3 years STANDARD_DEVIATION 7.5 • n=21 Participants	61.0 years STANDARD_DEVIATION 2.0 • n=8 Participants	58.0 years STANDARD_DEVIATION 15.1 • n=8 Participants	57.3 years STANDARD_DEVIATION 15.7 • n=24 Participants	59.8 years STANDARD_DEVIATION 8.9 • n=42 Participants	59.1 years STANDARD_DEVIATION 11.9 • n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	4 Participants n=8 Participants	2 Participants n=24 Participants	3 Participants n=42 Participants	15 Participants n=42 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	3 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=8 Participants	2 Participants n=8 Participants	4 Participants n=24 Participants	2 Participants n=42 Participants	20 Participants n=42 Participants

PRIMARY outcome

Timeframe: From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)

Population: All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.

Outcome measures

Outcome measures
Measure	MK-5108 200 mg BID (Panel 1) n=3 Participants Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 400 mg BID (Panel 1) n=3 Participants Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 800 mg BID (Panel 1) n=3 Participants Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1200 mg BID (Panel 1) n=3 Participants Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1500 mg BID (Panel 1) n=3 Participants Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1800 mg BID (Panel 1) n=3 Participants Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=6 Participants Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=6 Participants Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=5 Participants Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover) n=1 Participants After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover) n=3 Participants After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
Number of Participants Who Experienced an Adverse Event (AE)	3 Participants	3 Participants	3 Participants	3 Participants	3 Participants	3 Participants	6 Participants	6 Participants	5 Participants	1 Participants	3 Participants

PRIMARY outcome

Timeframe: Day 1 to Day 21 of study treatment (Cycle 1 for Panel 1, Panel 2, or Crossover)

Population: All participants that received one or more doses of study medication. Participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and DLTs were reported according to treatment received.

DLTs were AEs considered related to study drug that prevented escalation of the drug dose. Hematologic DLTs included any Grade 5 hematologic toxicity, Grade 4 neutropenia lasting for ≥7 days in duration, Grade 3 or Grade 4 neutropenia with fever \>38.5°C and/or infection requiring antibiotic or anti-fungal treatment, and Grade 4 thrombocytopenia (≤25.0 x 10\^9/L). Non-hematologic DLT was defined as any Grade 3, 4, or 5 non-hematologic toxicity, with the specific exceptions of: Grade 3 nausea or Grade 3 vomiting, Grade 3 diarrhea, or Grade 3 dehydration occurring in the setting of inadequate compliance with supportive care and lasting for \<48 hours, alopecia, inadequately treated hypersensitivity reactions, or Grade 3 elevated transaminases of ≤1 week in duration. Any drug-related AE leading to a dose modification of MK-5108, or any unresolved drug-related toxicity persisting\>6 weeks, was also considered a DLT.

Outcome measures

Outcome measures
Measure	MK-5108 200 mg BID (Panel 1) n=3 Participants Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 400 mg BID (Panel 1) n=3 Participants Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 800 mg BID (Panel 1) n=3 Participants Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1200 mg BID (Panel 1) n=3 Participants Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1500 mg BID (Panel 1) n=3 Participants Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1800 mg BID (Panel 1) n=3 Participants Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=6 Participants Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=6 Participants Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2) n=5 Participants Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover) n=1 Participants After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover) n=3 Participants After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
Number of Participants With Dose Limiting Toxicities (DLTs)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	2 Participants	0 Participants	0 Participants

Deaths: 0 deaths

MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Crossover)

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	MK-5108 200 mg BID (Panel 1) n=3 participants at risk Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 400 mg BID (Panel 1) n=3 participants at risk Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 800 mg BID (Panel 1) n=3 participants at risk Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1200 mg BID (Panel 1) n=3 participants at risk Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1500 mg BID (Panel 1) n=3 participants at risk Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1800 mg BID (Panel 1) n=3 participants at risk Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Panel 2) n=6 participants at risk Participants received 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Panel 2) n=6 participants at risk Participants received 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 225 mg BID + 60 mg/m2 Docetaxel (Panel 2) n=5 participants at risk Participants received 225 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Crossover) n=1 participants at risk After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Crossover) n=3 participants at risk After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
Psychiatric disorders Mental status changes	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Cardiac disorders Myocardial infarction	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Cardiac disorders Sinus bradycardia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Infection	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Pneumonia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Syncope	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Vascular disorders Thrombosis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.

Other adverse events

Other adverse events
Measure	MK-5108 200 mg BID (Panel 1) n=3 participants at risk Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 400 mg BID (Panel 1) n=3 participants at risk Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 800 mg BID (Panel 1) n=3 participants at risk Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1200 mg BID (Panel 1) n=3 participants at risk Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1500 mg BID (Panel 1) n=3 participants at risk Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 1800 mg BID (Panel 1) n=3 participants at risk Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).	MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Panel 2) n=6 participants at risk Participants received 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Panel 2) n=6 participants at risk Participants received 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 225 mg BID + 60 mg/m2 Docetaxel (Panel 2) n=5 participants at risk Participants received 225 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Crossover) n=1 participants at risk After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.	MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Crossover) n=3 participants at risk After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
Nervous system disorders Dizziness	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Dysphagia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Onychoclasis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	83.3% 5/6 • Number of events 9 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Leukopenia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 17 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	60.0% 3/5 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Lymphadenopathy	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 23 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 12 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	83.3% 5/6 • Number of events 10 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	60.0% 3/5 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Cardiac disorders Bradycardia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Cardiac disorders Pericardial effusion	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Cardiac disorders Sinus bradycardia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Ear and labyrinth disorders Ear discomfort	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Eye disorders Lacrimation increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Eye disorders Visual impairment	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Abdominal discomfort	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Abdominal distension	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Abdominal wall cyst	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Ascites	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Cheilitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Constipation	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 3/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 3/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Dry mouth	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Epigastric discomfort	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Faeces discoloured	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Flatulence	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Hypoaesthesia oral	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Nausea	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	60.0% 3/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Oesophagitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Oral pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Stomatitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Gastrointestinal disorders Vomiting	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 3/3 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Chest pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Chills	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Fatigue	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 3/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 12 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	60.0% 3/5 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 3/3 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Influenza like illness	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Infusion related reaction	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Infusion site erythema	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Local swelling	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Localised oedema	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Non-cardiac chest pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Oedema peripheral	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Pain	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Puncture site pain	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
General disorders Pyrexia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Bronchitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Cellulitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Cystitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Fungal infection	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Gastroenteritis viral	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Mucocutaneous candidiasis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Nasopharyngitis	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Pharyngitis streptococcal	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Sinusitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Infections and infestations Urinary tract infection	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Injury, poisoning and procedural complications Incision site complication	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Alanine aminotransferase increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Aspartate aminotransferase increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Bilirubin conjugated increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood alkaline phosphatase increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood bicarbonate decreased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood bilirubin increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood creatinine increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood lactate dehydrogenase increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood phosphorus decreased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood pressure increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Blood urine present	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Electrocardiogram QT prolonged	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Glucose urine present	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Neutrophil count decreased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Prostatic specific antigen increased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Prothrombin time prolonged	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations Weight decreased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Investigations White blood cell count decreased	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	60.0% 3/5 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 4/6 • Number of events 11 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 17 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 10 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypermagnesaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Muscle spasms	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Neck pain	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Nodule on extremity	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Burning sensation	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Dysgeusia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Extrapyramidal disorder	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Headache	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Hypoaesthesia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Neuropathy peripheral	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Paraesthesia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Parosmia	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Presyncope	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Nervous system disorders Sinus headache	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Psychiatric disorders Anxiety	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Psychiatric disorders Confusional state	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Psychiatric disorders Depression	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Psychiatric disorders Emotional distress	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Psychiatric disorders Insomnia	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Psychiatric disorders Mood swings	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Renal and urinary disorders Dysuria	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Renal and urinary disorders Pollakiuria	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Renal and urinary disorders Urinary incontinence	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Reproductive system and breast disorders Breast pain	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Reproductive system and breast disorders Penile oedema	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 3/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	66.7% 2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Dyspnoea paroxysmal nocturnal	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Haemoptysis	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	100.0% 1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Nasal dryness	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Orthopnoea	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Pulmonary artery thrombosis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Acne	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 9 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	50.0% 3/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	40.0% 2/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Increased tendency to bruise	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Lichenification	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Nail disorder	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Skin discolouration	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Skin disorder	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Skin exfoliation	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Skin hyperpigmentation	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	16.7% 1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Vascular disorders Flushing	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Vascular disorders Hypotension	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Vascular disorders Lymphoedema	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	33.3% 1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
Vascular disorders Phlebitis	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	20.0% 1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.	0.00% 0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days) All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.
Publication restrictions are in place

Restriction type: OTHER